Mestanolone
 |
|
| Clinical data | |
|---|---|
| Trade names | Andoron, Notandron |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Routes of administration |
Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 99% oral |
| Protein binding | yes |
| Metabolism | Hepatic |
| Biological half-life | ? |
| Excretion | Renal |
| Identifiers | |
|
|
| Synonyms | (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,4,5,6,7,8,9,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-one |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| ECHA InfoCard | 100.007.549 |
| Chemical and physical data | |
| Formula | C20H32O2 |
| Molar mass | 304.467 g/mol |
| 3D model (JSmol) | |
|
|
|
|
  (what is this?) (verify) |
|
Mestanolone (brand names Andoron, Notandron), also known as methylandrostanolone, is an orally active anabolic-androgenic steroid (AAS) and the 17α-methylated derivative of dihydrotestosterone (DHT).[1][2]
Side effects[edit]
Pharmacology[edit]
Due to inactivation by 3α-hydroxysteroid dehydrogenase (3α-HSD) in skeletal muscle, mestanolone is described as a very poor anabolic agent, similarly to DHT.[2] As mestanolone is already 5α-reduced, it cannot be aromatized and hence has no propensity for estrogenic side effects such as gynecomastia.[2] The drug also has no progestogenic activity.[2] Like other 17α-alkylated AAS, mestanolone is hepatotoxic.[2]
Chemistry[edit]
Mestanolone, also known as 17α-methyl-5α-dihydrotestosterone (17α-methyl-DHT) or as 17α-methyl-5α-androstan-17β-ol-3-one, is a synthetic, 17α-alkylated androstane steroid and a derivative of DHT differing from it only in the presence of a methyl group at the C17α position.[1][2] Close synthetic relatives of mestanolone include oxandrolone (2-oxa-17α-methyl-DHT), oxymetholone (2-hydroxymethylene-17α-methyl-DHT), and stanozolol (a derivative of 17α-methyl-DHT (mestanolone) with a pyrazole ring fused to the A ring).[1][2]
